WebJan 10, 2024 · SAN FRANCISCO & NEW YORK-- ( BUSINESS WIRE )-- Nektar Therapeutics (Nasdaq:NKTR) and Bristol-Myers Squibb Company (NYSE:BMY) … WebFeb 14, 2024 · Nektar agreed to book revenue for worldwide sales of NKTR-214, in return for the companies splitting global profits for NKTR-214, with Nektar receiving 65% and BMS 35%. BMS will retain 100% of ...
End of the line for BMS, Nektar
WebApr 15, 2024 · Bristol Myers Squibb and Nektar Therapeutics ended their global clinical program for a potential bladder cancer and renal cell carcinoma treatment, causing the latter's shares to drop over 24% to $4.68 per share on Thursday. The decision was mutual and was based on disappointing results from analyses of two late-stage trials combining ... WebSep 18, 2024 · The study evaluated the efficacy of Bempeg (Nektar-214) combined with BMT's Opdivo (Nivolumab). The findings of the study were in no way equivocal. 52.6% of patients saw a meaningful reduction in ... aggregate information definition
Press Release - Nektar
WebMar 14, 2024 · Mar. 14, 2024, 07:38 AM. (RTTNews) - Bristol Myers Squibb (BMY) and Nektar Therapeutics (NKTR) announced Monday an update following the first analysis of … WebSep 9, 2024 · The European Society for Medical Oncology (ESMO) conference is serving as a post-mortem on the trials that sunk the multi-billion-dollar partnership between Bristol-Myers Squibb and Nektar Therapeutics. Investigators will present the data from the failed Phase I/II PIVOT-02 study in metastatic melanoma, which showed Nektar’s … WebThe drug was part of BMS' commitment of up to $3.6 billion to Nektar in 2024, which was the largest licensing deal in biotech history at the time. aggregate industries locations in colorado